Ddavp

Polyuria, Nocturia, Polydipsia + 14 more

Treatment

11 Active Studies for Ddavp

What is Ddavp

Desmopressin

The Generic name of this drug

Treatment Summary

Desmopressin (dDAVP) is a synthetic hormone used to treat conditions that involve excessive urination, such as nocturia, diabetes insipidus, and primary nocturnal enuresis. It also helps treat mild classical hemophilia and von Willebrand's disease for minor surgeries. Desmopressin is an improved version of the naturally occurring hormone vasopressin, and it was approved by the FDA in 2018. It is available in a variety of forms, including intranasal solution, intravenous solution, oral tablets, and sublingual tablets.

Ddavp

is the brand name

image of different drug pills on a surface

Ddavp Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ddavp

Desmopressin

1978

101

Effectiveness

How Ddavp Affects Patients

Desmopressin is a drug that helps the body retain water by mimicking the action of a natural hormone, anti-diuretic hormone (ADH). It is more effective than ADH at increasing the levels of factor VIII in patients with hemophilia and von Willebrand's disease. Desmopressin does not increase blood pressure like some other drugs, and is much less effective when taken as a nasal spray than as an injection.

How Ddavp works in the body

When desmopressin binds to V2 receptors in the kidneys, it causes cells in the distal tubule and collecting ducts to insert water channels, called aquaporins, into the membrane. This increases the permeability of the membrane to water.

When to interrupt dosage

The measure of Ddavp is contingent upon the diagnosed malady, including Minor Surgical Procedures, Pituitary Gland and Surgery, Hemophilia A. The portion of dosage is contingent upon the approach of delivery featured in the table beneath.

Condition

Dosage

Administration

Nocturia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Polydipsia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

von Willebrand Disease

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Pituitary Diseases

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Uremia

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Hemorrhage

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

von Willebrand Disease

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Hemorrhage

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Diabetes Insipidus, Neurogenic

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Pituitary Surgery

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Polyuria

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Nocturnal Enuresis

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Minor Surgical Procedures

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Polyuria

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Hemophilia A

0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation

Oral, , Tablet - Oral, Tablet, Nasal, Solution, Solution - Nasal, Solution - Intravenous, Injection, solution - Intravenous; Subcutaneous, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Spray, metered - Nasal, Spray, metered, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Intravenous; Subcutaneous, Tablet - Sublingual, Intravenous, Injection, solution, Injection, Solution - Intravenous; Subcutaneous, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous

Warnings

Ddavp Contraindications

Condition

Risk Level

Notes

Hyponatremia

Do Not Combine

Renal Insufficiency

Do Not Combine

Hyponatremia

Do Not Combine

There are 20 known major drug interactions with Ddavp.

Common Ddavp Drug Interactions

Drug Name

Risk Level

Description

1-benzylimidazole

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 1-benzylimidazole.

2,5-Dimethoxy-4-ethylamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylamphetamine.

2,5-Dimethoxy-4-ethylthioamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.

4-Bromo-2,5-dimethoxyamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Bromo-2,5-dimethoxyamphetamine.

4-Methoxyamphetamine

Minor

The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Methoxyamphetamine.

Ddavp Toxicity & Overdose Risk

Taking too much desmopressin can cause a low level of sodium, or hyponatremia. Symptoms of this include seizures, disorientation, confusion, drowsiness, or a continuing headache, as well as an irregular heartbeat and swelling. If you think you have taken too much desmopressin, lower the dose or stop taking it. Have your sodium levels checked by a doctor, and start any necessary treatment.

image of a doctor in a lab doing drug, clinical research

Ddavp Novel Uses: Which Conditions Have a Clinical Trial Featuring Ddavp?

There are presently 30 active studies assessing the potential of Ddavp to mitigate Polyuria, Hemophilia A and Hemophilia.

Condition

Clinical Trials

Trial Phases

Pituitary Diseases

0 Actively Recruiting

Hemorrhage

0 Actively Recruiting

Pituitary Surgery

1 Actively Recruiting

Phase 2

von Willebrand Disease

0 Actively Recruiting

Hemophilia A

3 Actively Recruiting

Phase 3, Phase 1

Uremia

0 Actively Recruiting

Nocturia

7 Actively Recruiting

Not Applicable, Phase 4

Polyuria

0 Actively Recruiting

Minor Surgical Procedures

0 Actively Recruiting

von Willebrand Disease

0 Actively Recruiting

Polydipsia

0 Actively Recruiting

Diabetes Insipidus, Neurogenic

0 Actively Recruiting

Hemophilia A

0 Actively Recruiting

Polyuria

0 Actively Recruiting

Hemorrhage

0 Actively Recruiting

Hemophilia A

0 Actively Recruiting

Nocturnal Enuresis

0 Actively Recruiting

Ddavp Reviews: What are patients saying about Ddavp?

5

Patient Review

10/14/2010

Ddavp for Diabetes Insipidus

We've had great success with this medication for my two kids. My son took it for about a year with no problems whatsoever, and now my daughter is taking it too. So far so good!

5

Patient Review

11/30/2010

Ddavp for Bedwetting

This treatment has been essential for me. I have a condition called panhypopituitarism, which means that my pituitary gland was removed. This medication helps me to control my urine flow and has literally saved my life.

5

Patient Review

4/6/2014

Ddavp for Diabetes Insipidus

Unfortunately, we didn't see any results from using this treatment. We followed the instructions to a tee and even doubled up when advised by our doctor, but saw no improvement. This was very frustrating and a waste of money.

5

Patient Review

9/7/2010

Ddavp for Diabetes Insipidus

Unfortunately, this treatment didn't work for my son at all.

5

Patient Review

1/14/2013

Ddavp for Diabetes Insipidus

After being diagnosed with DI, I tried the nasal spray for a year. But I wasn't convinced that it always worked, so I switched to tablets. After several changes in dosage, I feel like we've finally got it right. This medicine has honestly changed my life--I felt like I had gotten my life back. However, now I am wondering if it is changing my mood because I am feeling depressed recently.

4.7

Patient Review

3/2/2016

Ddavp for Bedwetting

Despite trying a number of things, my son was still wetting the bed every single night. Finally, we tried this medication and it has not worked at all. We're going to try doubling the dosage tonight and see if that makes any difference. Will update soon.

4

Patient Review

9/28/2012

Ddavp for Diabetes Insipidus

My daughter has been using this treatment for more than two years with great success. She uses the nasal spray, one squirt each night. However, I have noticed that she has gained weight in the last two years and I'm not sure if it's from the medicine or not. Are there any other alternatives to bedwetting than desmopressin?

3.7

Patient Review

8/1/2010

Ddavp for Diabetes Insipidus

My 9-year-old daughter tried this medication for bedwetting, but it didn't work at all. Additionally, she had a severe allergic reaction after just three days of use (rash).

2.3

Patient Review

7/23/2015

Ddavp for Bedwetting

Though it's not as effective as the nasal spray, this pill is more even in its effects and gentle on my nose. The only downside is that I have to remember to take it three times a day.

2.3

Patient Review

5/14/2010

Ddavp for Bedwetting

2

Patient Review

6/20/2010

Ddavp for Bedwetting

1.7

Patient Review

4/5/2011

Ddavp for Bedwetting

We just started this medication last night, and my daughter is already seeing some results. However, I'm concerned about the potential side effects of this drug, specifically with regards to mood changes or obsessive behaviors in children. Has anyone else experienced this?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ddavp

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is DDAVP given for?

"DDAVP is used to help stop bleeding in patients with von Willebrand's disease or mild hemophilia A by causing the release of von Willebrand's antigen from the platelets and the cells that line the blood vessels where it is stored."

Answered by AI

What is the difference between desmopressin and DDAVP?

"This medication is used to treat diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, and high blood urea levels."

Answered by AI

What is DDAVP in diabetes insipidus?

"Desmopressin is a synthetic form of vasopressin that helps decrease the amount of urine made by working on the kidneys."

Answered by AI

How does DDAVP work for bleeding?

"DDAVP works by increasing the levels of factor VIII and von Willebrand factor in the blood, which typically last for 12 to 24 hours. This effect is usually enough to control minor bleeding and to prevent bleeding during minor operations, such as dentistry."

Answered by AI

Clinical Trials for Ddavp

Image of University of Pittsburgh in Pittsburgh, United States.

Treatment for Nocturia

65+
Female
Pittsburgh, PA

The goal of this clinical trial is to examine and compare the effect of behavioral sleep treatment: BBTI (brief behavioral treatment of insomnia) and brief mindfulness (MI), independently and combined vs control on frequency of nighttime awakenings to void (nocturia) and on nighttime urine production in older women over the age 65 years with nocturia. To study the effect of these treatments, participants will be randomly assigned to one of the following groups 1) BBTI alone, 2) MI alone, 3) BBTI+MI, or 4) control: sleep information only without any structured sleep or mindfulness therapy. The study aims to examine the effect of these therapies at end-of-treatment (week 4), as well sustained effects at 3- and 6-months. The main questions the study aims to answer are: 1. do these treatments reduce the frequency of nighttime awakenings to void 2. do these treatments reduce the volume of nighttime urine production 3. do these treatments improve sleep quality Frequency of nocturia and sleep quality will be assessed via questionnaires and nighttime urine volume using bladder-sleep diaries which is 3-day record participants will complete at home documenting every time they go to the bathroom and volume they voided. In addition, sleep and sleep interruptions will also be assessed using an FDA-cleared home sleep testing device called Zmachine®.

Waitlist Available
Has No Placebo

University of Pittsburgh

Shachi Tyagi, MD, MS

Have you considered Ddavp clinical trials?

We made a collection of clinical trials featuring Ddavp, we think they might fit your search criteria.
Go to Trials

Have you considered Ddavp clinical trials?

We made a collection of clinical trials featuring Ddavp, we think they might fit your search criteria.
Go to Trials